Foundation Fighting Blindness
Foundation Fighting Blindness
Foundation Fighting Blindness
The Foundation Fighting Blindness is the driving force in the global development of treatments and cures for blinding diseases. To learn more, go to FightingBlindness.org.
Belite Bio submits new drug application to FDA for its Stargardt treatment
Belite Bio submits new drug application to FDA for its Stargardt treatment by Foundation Fighting Blindness
Jul 6
3 min
Eye on the Cure Podcast | Episode 101: Dr. Patrick Staropoli
New host Maddie Mossman interviews retinal surgeon Dr. Staropoli, the first medical doctor to win a NASCAR race.
Jul 1
42 min
Potential Oral Stargardt Treatment Advances to Phase 3 Clinical Trial
Promising oral treatment moves closer for Stargardt patients.
Jun 18
4 min
Foundation Fighting Blindness Celebrates Bennett, Maguire, and High's Breakthrough Prize for Revolutionary Gene Therapy
2020 Llura Liggett Gund Award recipient honored for pioneering gene therapy that transformed vision research
May 11
4 min
Atsena Therapeutics Advances to Pivotal Phase 3 Trial for X-Linked Retinoschisis
Data monitoring committee recommends proceeding with registration-enabling study for ATSN-201
Apr 21
3 min
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) by Foundation Fighting Blindness
Apr 16
3 min
Opus Genetics Secures $155 Million Financing to Accelerate Gene Therapy Pipeline
Strategic funding extends cash runway through 2029 and advances multiple inherited retinal disease programs
Apr 8
2 min
VeonGen Reports Promising Clinical Progress for Stargardt Disease Gene Therapy
VG801 shows sustained vision improvements through 12 months with favorable safety profile
Mar 26
2 min
Sumitomo Pharma Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment
Potential cell therapy, DSP-3077, gains special regulatory status to support development for inherited retinal disease.
Mar 24
2 min
Octant Bio Begins Clinical Testing Oral Treatment for Rhodopsin-Related Retinitis Pigmentosa
First-of-its-kind small molecule therapy targets protein misfolding at the root of RHO-adRP
Mar 11
2 min
Load more